List view / Grid view
Product recalls due to contamination issues can be extremely costly for companies, in addition to the associated health implications. In this article, Marc Baiget Francesch explores the potential risks associated with N-nitrosodimethylamine (NDMA) contamination, why is it such a frequent contaminant and how to detect and eliminate the risks.
A Fortune report reveals the best 10 places to work in the US biopharmaceutical industry.
Repurposing existing drugs can be attractive as the process is often less risky, more cost effective and can be undertaken in less time. This article discusses the logic behind drug repurposing and the approaches that are currently being explored.
A study comparing the V-Go device administering regular human insulin and rapid acting insulin analogues found they were equally effective and safe at controlling blood glucose.
Safety updates to labels of SGLT2 inhibitors will recommend temporary discontinuation of these medications before scheduled surgery, says the FDA.
The US FDA has granted Fast Track designation to Jardiance® for the treatment of chronic kidney disease.
The EMA’s human medicines committee (CHMP) recommended fifteen medicines for various approvals at its January 2020 meeting; with ten drugs receiving marketing authorisation recommendations and five receiving positive opinions for specific treatments.
Farxiga, a treatment to reduce the risk of heart failure in patients with type 2 diabetes has been approved by the FDA.
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
The EMA has suggested seven treatments to be granted marketing authorisations and also advocated indication extension for eight drugs.
With the approval of the treatment, Rybelsus, there is a new option for treating type 2 diabetes without injections.
Seven medications have been suggested for removal from prescriptions by the NHS after a public consultation.
The FDA has approved an injection for use in patients aged 10-17 to treat type 2 diabetes.
It has been announced that a Marketing Authorisation Application (MAA) has been submitted to the European Medicines Agency (EMA) for oral semaglutide.
Results of a phase III clinical trial suggest that dual antiplatelet therapy may improve outcomes for patients with established coronary artery disease (CAD) and type 2 diabetes....
